SCHEMBL9945371

SCHEMBL9945371

CC/C=N/Oc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.38
CA4 P22748 1/20 0.37
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
MAOB P27338 1/20 0.35
TSHR P16473 1/20 0.35
KCNA3 P22001 1/20 0.34
ATM Q13315 1/20 0.34
CHRNB2 P17787 2/20 0.34
CHRNB4 P30926 2/20 0.34
CHRNA3 P32297 2/20 0.34
CHRNA7 P36544 2/20 0.34
CHRNA4 P43681 2/20 0.34
RELA Q04206 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18672790 0.80 LTA4H (0.43) LTA4HALDH1A1LMNAHTTMAOB
SCHEMBL27534466 0.78 ALDH1A1 (0.40) LTA4HCA4ALDH1A1LMNANPC1
SCHEMBL9945420 0.75 KCNA3 (0.47) LTA4HALDH1A1KCNA3CHRNB2CHRNB4
SCHEMBL4151574 0.75 CA4 (0.42) LTA4HCA4ALDH1A1LMNANPC1
SCHEMBL14667490 0.75 CA4 (0.42) LTA4HCA4ALDH1A1LMNANPC1
SCHEMBL22129143 0.74 LTA4H (0.43) LTA4HCA4ALDH1A1LMNATSHR
SCHEMBL9945604 0.74 KCNA3 (0.50) LTA4HALDH1A1KCNA3CHRNB2CHRNB4
SCHEMBL16327311 0.72 HPGD (0.35) ALDH1A1LMNANPC1POLBHTT
SCHEMBL8657434 0.72 KCNA3 (0.39) LTA4HALDH1A1KCNA3
SCHEMBL17276616 0.71 MAPT (0.50) LTA4HALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345713-B2 Compounds as modulators of TLR2 signaling NEUROPORE THERAPIES, INC. (US) 2022-05-31 US disclosed
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2021-01-28 US disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 LTA4H 1265/4885CA4 1809/4885ALDH1A1 43/4885
US-11345713-B2 Compounds as modulators of TLR2 signaling TLR2, TLR4, TLR3 LTA4H 1288/4885CA4 4847/4885ALDH1A1 4464/4885
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 LTA4H 1288/4885CA4 4847/4885ALDH1A1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.